Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine

<p>Abstract</p> <p>Background</p> <p>Hyperhomocysteinemia and lipid abnormalities are commonly found in patients with chronic renal failure; both are recognized as risk factors for atherosclerosis. The homocysteine-lowering effect of pyridoxine is controversial. This st...

Full description

Bibliographic Details
Main Authors: Touceda Luis A, Giammona Ana M, de Gómez Dumm Nelva T
Format: Article
Language:English
Published: BMC 2003-09-01
Series:Lipids in Health and Disease
Subjects:
Online Access:http://www.Lipidworld.com/content/2/1/7
id doaj-2676a590f66d42068b99dd9916ed53b4
record_format Article
spelling doaj-2676a590f66d42068b99dd9916ed53b42020-11-24T23:21:22ZengBMCLipids in Health and Disease1476-511X2003-09-0121710.1186/1476-511X-2-7Variations in the lipid profile of patients with chronic renal failure treated with pyridoxineTouceda Luis AGiammona Ana Mde Gómez Dumm Nelva T<p>Abstract</p> <p>Background</p> <p>Hyperhomocysteinemia and lipid abnormalities are commonly found in patients with chronic renal failure; both are recognized as risk factors for atherosclerosis. The homocysteine-lowering effect of pyridoxine is controversial. This study was performed to determine the effect of a high dose of pyridoxine (300 mg i.v. three times a week) on plasma and red blood cell lipid profile and plasma homocysteine concentration in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (basal 1), after 30 and 60 days of treatment and 4 months after withdrawal (basal 2).</p> <p>Results</p> <p>Pyridoxine supplementation induced a significant decrease in total plasma homocysteine level and also a lowering effect in plasma total cholesterol and triglycerides. These biochemical data increased when the samples were taken at basal 2, reaching the levels obtained at the beginning of the experiment. LDL cholesterol increased whereas HDL cholesterol was reduced during the treatment. In erythrocyte membranes vitamin B6 therapy enhanced the cholesterol/phospholipid ratio as well as the fluorescence anisotropy of diphenyl-hexatriene.</p> <p>Conclusions</p> <p>We conclude that high doses of pyridoxine represent an effective strategy to ameliorate both plasma homocysteine levels and lipid profiles in chronic renal failure patients, protecting them from atherosclerosis. Further research using a long-term treatment would be necessary in an attempt to restore the fatty acid pattern and the fluidity of red cell membranes.</p> http://www.Lipidworld.com/content/2/1/7cholesterolchronic renal failurehomocysteinepolyunsaturated fatty acidspyridoxinetriglyceride
collection DOAJ
language English
format Article
sources DOAJ
author Touceda Luis A
Giammona Ana M
de Gómez Dumm Nelva T
spellingShingle Touceda Luis A
Giammona Ana M
de Gómez Dumm Nelva T
Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
Lipids in Health and Disease
cholesterol
chronic renal failure
homocysteine
polyunsaturated fatty acids
pyridoxine
triglyceride
author_facet Touceda Luis A
Giammona Ana M
de Gómez Dumm Nelva T
author_sort Touceda Luis A
title Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
title_short Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
title_full Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
title_fullStr Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
title_full_unstemmed Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
title_sort variations in the lipid profile of patients with chronic renal failure treated with pyridoxine
publisher BMC
series Lipids in Health and Disease
issn 1476-511X
publishDate 2003-09-01
description <p>Abstract</p> <p>Background</p> <p>Hyperhomocysteinemia and lipid abnormalities are commonly found in patients with chronic renal failure; both are recognized as risk factors for atherosclerosis. The homocysteine-lowering effect of pyridoxine is controversial. This study was performed to determine the effect of a high dose of pyridoxine (300 mg i.v. three times a week) on plasma and red blood cell lipid profile and plasma homocysteine concentration in twelve chronic renal failure patients on regular hemodialysis. Fasting blood samples were taken at the beginning of the study (basal 1), after 30 and 60 days of treatment and 4 months after withdrawal (basal 2).</p> <p>Results</p> <p>Pyridoxine supplementation induced a significant decrease in total plasma homocysteine level and also a lowering effect in plasma total cholesterol and triglycerides. These biochemical data increased when the samples were taken at basal 2, reaching the levels obtained at the beginning of the experiment. LDL cholesterol increased whereas HDL cholesterol was reduced during the treatment. In erythrocyte membranes vitamin B6 therapy enhanced the cholesterol/phospholipid ratio as well as the fluorescence anisotropy of diphenyl-hexatriene.</p> <p>Conclusions</p> <p>We conclude that high doses of pyridoxine represent an effective strategy to ameliorate both plasma homocysteine levels and lipid profiles in chronic renal failure patients, protecting them from atherosclerosis. Further research using a long-term treatment would be necessary in an attempt to restore the fatty acid pattern and the fluidity of red cell membranes.</p>
topic cholesterol
chronic renal failure
homocysteine
polyunsaturated fatty acids
pyridoxine
triglyceride
url http://www.Lipidworld.com/content/2/1/7
work_keys_str_mv AT toucedaluisa variationsinthelipidprofileofpatientswithchronicrenalfailuretreatedwithpyridoxine
AT giammonaanam variationsinthelipidprofileofpatientswithchronicrenalfailuretreatedwithpyridoxine
AT degomezdummnelvat variationsinthelipidprofileofpatientswithchronicrenalfailuretreatedwithpyridoxine
_version_ 1725571689595535360